Tag Archives: Obesity treatment

For years, glucagon-like peptide-1 (GLP-1) receptor agonists have dominated conversations about diabetes and obesity treatment. However, another hormone is quietly returning to the spotlight. Amylin diabetes therapy is making a comeback as researchers develop a new generation of drugs designed to improve blood glucose control and support weight management. Amylin …

For decades, glucagon has been viewed as insulin’s opposite. While insulin lowers blood glucose, glucagon raises it by signaling the liver to release stored sugar into the bloodstream. Because of this, glucagon has traditionally been considered a hormone to suppress in people living with type 2 diabetes. However, modern research …

As demand for GLP-1 receptor agonists continues to outpace supply, many patients have turned to compounded medications obtained through telehealth companies, medical spas, wellness clinics, and compounding pharmacies. While these products may improve access for some individuals, they also introduce important clinical, regulatory, and medicolegal challenges. Providers increasingly encounter patients …

For many people living with type 2 diabetes, treatment eventually reaches a frustrating crossroads. Despite multiple medications, including GLP-1 receptor agonists, SGLT2 inhibitors, and insulin, glycemic targets may remain difficult to achieve. Meanwhile, bariatric surgery can produce major metabolic benefits, but its invasiveness limits acceptance for many patients. This treatment …

The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are helping patients achieve levels of weight loss that were previously difficult to attain without bariatric surgery. However, as clinicians celebrate these advances, a …

Everything seems to be working perfectly until it suddenly isn’t. A patient is losing weight steadily, HbA1c levels are improving, and confidence is high during every follow-up visit. Then progress slows. The scale barely changes. Blood sugar readings stop improving. Patients start asking whether the medication has stopped working, while …

Losing 30 pounds may sound like an undeniable success story. However, what if part of that weight loss comes from muscle instead of fat? As more patients use GLP-1 medications such as semaglutide and tirzepatide, clinicians are starting to ask an important question: are these drugs quietly contributing to the …

A patient starts semaglutide through a telehealth platform, receives nutrition advice from a wellness clinic, and later visits a primary care physician for worsening gastrointestinal symptoms. None of the providers can see the full treatment picture. Situations like this are becoming increasingly common as GLP-1 medications move across multiple corners …

A patient loses 30 pounds, lowers their A1C, and improves their blood pressure within months of starting a GLP-1 medication. Stories like these are hard to ignore, and they have helped fuel growing enthusiasm around drugs like Ozempic, Wegovy, and Mounjaro. Yet as prescriptions continue to expand beyond high-risk diabetes …

The rapid rise of GLP-1 receptor agonists has transformed diabetes treatment and obesity management over the past decade. However, high prices and limited insurance coverage continue to restrict access for many patients. As patents evolve and global pharmaceutical markets shift, conversations about lower-cost GLP-1 therapies are gaining momentum. Clinicians are …